• A SALOMY MONICA DIYYA College of Medicine, Department of Pharmacy, Komar University of Science and Technology
  • NOEL VINAY THOMAS College of Science, Department of Medical Laboratory Science, Komar University of Science and Technology.




SARS CoV-2, Antiviral drugs, Chloroquine, Interferon therapy, Monoclonal antibodies, Vaccine therapy, Extracorporeal membrane oxygenation


Covid-19, an infectious disease caused by coronavirus spreads by salivary droplets or nasal discharge from an infected person during sneezing or coughing. This infectious disease is caused by a novel coronavirus, SARS CoV-2 shares the same structure with that of the virus that causes severe acute respiratory syndrome (SARS). Most of the people who are infected with Covid-19 will experience respiratory illness and can be treated with antiviral drugs and or a combination of antiviral drugs and supportive therapies. Many medical investigational approaches are being investigated to design possible treatment strategies and possible avenues for Covid-19 therapy. Potential strategies for the treatment of Covid-19 include antiviral medication, the combination of interferons and antiviral drugs, interleukin inhibitors. Recent studies show that the use of plasma from survivors can help patients in recovering from the disease. This approach of using plasma is termed as convalescent plasma therapy. Another newer technology that includes the construction of a recombinant vaccine is gaining importance for further investigation. The other major approaches include the therapeutic use of serine protease inhibitors, chloroquine, hydroxychloroquine, ammonium chloride in definite doses. New study approaches include investigation on the production of monoclonal antibodies has gained a way for further clinical research. An effective supportive therapy includes extracorporeal membrane oxygenation could be considered as rescued therapy for the patients having respiratory distress. After sufficient clinical data is obtained and by taking all these approaches into consideration, the treatment protocol can be designed to treat Covid-19 successfully.


Download data is not yet available.


Pneumonia of unknown cause China: disease outbreak news. Geneva. World Health Organisation; 2020.

Draft landscape of COVID-19 candidate vaccines. Geneva. World Health Organisation; 2020.

Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore 2007;36:438-43.

Tim Smith, Tony Prosser. COVID-19 drug therapy-potential options, clinical drug information. Clinical Solutions 2020. p. 1-4.

Afsaneh Gray. The hunt for an effective treatment for COVID-19. Pharm J 2020;304:7936.

Kayvon Modjarrad. Treatment strategies for middle east respiratory syndrome coronavirus. J Virus Erad 2016;2:1-4.

Momattin H, Al Ali AY, Al Tawfiq JA. A systematic review of therapeutic agents for the treatment of the middle east respiratory syndrome coronavirus (MERS-Cov). Travel Med Infect Dis 2019;30:9-18.

Loutfy MR, Blatt LM, Siminovitch KA. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. J Am Med Assoc 2003;290:3222–8.

Sarah Zhang. America needs plasma from COVID-19 survivors now. The Atlantic; 2020.

Abby Olena. Newer vaccine technologies deployed to develop COVID-19 shot. The Scientist; 2020.

Junyi Guo MD, Zheng Huang. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infections. J Am Heart Assoc 2020;9:9.

COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. European Medicines Agency; 2020.

Martin J Vincent, Eric Bergeron. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

Momattin H, Al Ali AY, Al Tawfiq JA. A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-Cov). Travel Med Infect Dis 2019;30:9-18.

Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS: Likely site of vulnerability on SARS-CoV-2 virus determined. Scripps Research Institute. Science Daily; 2020.

Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.

Hong X, Xiong J, Feng Z, Shi Y. Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?. Int J Inf Diseases 2020;94:78-80.

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO; 2020.

Al Tameemi, Kabakli. Novel coronavirus (2019-nCoV). Asian J Pharm Clin Res 2020;13:22-7.



How to Cite

DIYYA, A. S. M., and N. V. THOMAS. “POTENTIAL THERAPEUTIC AVENUES FOR COVID-19 THERAPY”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 12, no. 8, Aug. 2020, pp. 11-14, doi:10.22159/ijpps.2020v12i8.38023.



Review Article(s)